Wells Fargo initiated coverage on STAAR Surgical with a new price target
$STAA
Ophthalmic Goods
Health Care
Wells Fargo initiated coverage of STAAR Surgical with a rating of Equal Weight and set a new price target of $17.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/21/2025 | $17.00 | Equal Weight | Wells Fargo |
| 2/12/2025 | Buy → Hold | Jefferies | |
| 2/12/2025 | $45.00 → $17.00 | Outperform → Neutral | Mizuho |
| 2/12/2025 | Buy → Neutral | BTIG Research | |
| 2/12/2025 | Outperform → Mkt Perform | William Blair | |
| 7/15/2024 | $50.00 → $37.00 | Equal-Weight → Underweight | Morgan Stanley |
| 6/11/2024 | $46.00 | Neutral → Buy | BTIG Research |
| 3/11/2024 | $30.00 → $50.00 | Hold → Buy | Stifel |
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that Deborah Andrews has been appointed Chief Financial Officer, effective June 25, 2025. Ms. Andrews has served as Interim CFO since March 2025, and she previously served as STAAR's CFO from 2007-2013 and 2017-2020. "Deborah has blended seamlessly with the leadership team, and we quickly realized that her deep knowledge of STAAR and her skills, abilities, and approach made her the perfect choice to be STAAR's next CFO," said the Company's CEO and Board member, Stephen Farrell. "In the last few months, Deborah has
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that management will participate in the following upcoming conferences: Stifel 2025 Virtual Ophthalmology Forum Date: Tuesday, May 27, 2025 Format: Meetings and Webcast Fireside Chat Webcast: 2:00 PM ET, Webcast Link Wells Fargo 2025 West Coast Bus Tour Date: Thursday, May 29, 2025 Location: Laguna Beach, CA Format: Fireside Chat; No Webcast William Blair 45th Annual Growth Stock Conference Date: Wednesday, June 4, 2025 Location: Chicago, IL Format: Meetings and Webcast Slide Presentation Webcast: 9:40 AM ET, Webcast
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $30 million of its outstanding common stock. "Our decision to initiate a share repurchase program underscores the Board's and management's confidence in STAAR's future and our ability to return to sustainable, profitable growth," said Stephen C. Farrell, Chief Executive Officer of STAAR Surgical. "With a strong balance sheet, no debt, and clear progress in our cost optimization and strategic priorities, we
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
Wells Fargo initiated coverage of STAAR Surgical with a rating of Equal Weight and set a new price target of $17.00
Jefferies downgraded STAAR Surgical from Buy to Hold
Mizuho downgraded STAAR Surgical from Outperform to Neutral and set a new price target of $17.00 from $45.00 previously
8-K - STAAR SURGICAL CO (0000718937) (Filer)
8-K - STAAR SURGICAL CO (0000718937) (Filer)
8-K - STAAR SURGICAL CO (0000718937) (Filer)
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that Deborah Andrews has been appointed Chief Financial Officer, effective June 25, 2025. Ms. Andrews has served as Interim CFO since March 2025, and she previously served as STAAR's CFO from 2007-2013 and 2017-2020. "Deborah has blended seamlessly with the leadership team, and we quickly realized that her deep knowledge of STAAR and her skills, abilities, and approach made her the perfect choice to be STAAR's next CFO," said the Company's CEO and Board member, Stephen Farrell. "In the last few months, Deborah has
Stephen C. Farrell appointed CEO to succeed Tom Frinzi Elizabeth Yeu, M.D. elected Board Chair STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced a leadership transition. Stephen C. Farrell, current Lead Independent Director of the STAAR Board of Directors, has been appointed President and CEO, effective February 26, 2025. Tom Frinzi, STAAR's current President and CEO, will remain with the Company in an advisory role through January 2026 to support the leadership transition and build upon STAAR's strong relationships in the ophthalmic community. "We are pleased to
New Appointments Underscore Commitment to Driving Innovation and Industry-Leading Growth STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel. Both will serve on the Company's executive committee and report to Tom Frinzi, STAAR Surgical's President and CEO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240501408389/en/Nancy Sabin, Chief Marketing Officer, STAAR Surgical (Photo:
SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)
SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)
SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $30 million of its outstanding common stock. "Our decision to initiate a share repurchase program underscores the Board's and management's confidence in STAAR's future and our ability to return to sustainable, profitable growth," said Stephen C. Farrell, Chief Executive Officer of STAAR Surgical. "With a strong balance sheet, no debt, and clear progress in our cost optimization and strategic priorities, we
China ICL Procedure Trends Improving Tariff Mitigation Activities Implemented Cost Controls and Restructuring Initiated to Reduce SG&A Run Rate Earnings Call and Webcast Today at 5:15 p.m. Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the first quarter ended March 28, 2025. First Quarter 2025 Financial Overview Net sales of $42.6 million down 45% Y/Y due to planned reduction of channel inventory in China Net Sales Excluding China of $42.2 million up 9% Y/Y reflecting growth in all key markets Gross margin at 65.8% vs. 78.9% year ago due
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to